Innate Pharma announces its financial calendar for 2018
Number of shares and voting rights of Innate Pharma as at december 4, 2017
Innate Pharma provides an update on Lirilumab
Third quarter 2017 report
Final results of the dose-escalation part from the phase I trial evaluating IPH4102 in patients with advanced cutaneous T-cell lymphomas presented at the EORTC CLTF meeting
First half of 2017: delivering key clinical data and strengthening the pipeline
ICI conference 2017: new preclinical data further strengthen the rationale of IPH5401 and monalizumab for cancer treatments and in combination with anti-PD-1/PD-L1
Number of shares and voting rights of Innate Pharma as at August 4, 2017
Issuance by Innate Pharma of 3,343,748 ordinary shares to Novo Nordisk A/S in consideration for rights in anti-C5aR
Results of Annual General Meeting and changes to Innate Pharma’s governance and management team
